Clinical guidelines worldwide (comparison)

Synthesis comparing national and international RLS clinical practice guidelines (diagnosis and treatment algorithms) across the US, Europe (international and national), Germany, France, Spain, Japan, Korea, and international bodies (IRLSSG/EURLSSG, World Sleep Society), plus the historical evolution of the US guidelines from 2004-2026. All claims below cite a study note filename (in knowledge-base/studies/) or a PMID. Medical disclaimer: nothing here is individual medical advice; guidelines vary by country and any medication change - especially tapering a dopamine agonist - must be done only under physician supervision and never stopped abruptly (dopamine agonist withdrawal syndrome, DAWS, can be severe).

What is established (grade A/B)

• Alpha-2-delta ligands (gabapentin, gabapentin enacarbil, pregabalin) are now the most consistently endorsed first-line drug class across recent guidelines, and this rests on grade-A/B trial evidence of lower augmentation risk than dopamine agonists (2.1% pregabalin vs 7.7% pramipexole at 40-52 weeks in a 719-patient RCT: 2014-allen-nejm-pregabalin-pramipexole-augmentation.md; 9.2% vs 6.0% placebo at 6 months for pramipexole: 2011-hogl-pramipexole-6-month-augmentation-rct.md). This evidence is reflected in strong recommendations for gabapentin enacarbil, gabapentin, and pregabalin in the 2025 AASM guideline (PMID 39324694; 2025-winkelman-aasm-guideline-rls.md), the 2026 updated Mayo/RLS-Foundation algorithm (2026-silber-updated-rls-management-algorithm.md), the 2016 IRLSSG/EURLSSG augmentation guideline (2016-garcia-borreguero-augmentation-prevention-treatment-guidelines.md), and the 2018 Movement Disorder Society evidence review (2018-winkelmann-mds-evidence-based-review.md).
• A serum ferritin threshold of approximately 75 ug/L (or ng/mL) to trigger iron supplementation is now consistent across the major guidelines that specify a number: the 2025 AASM guideline (oral or IV iron if ferritin <=75 ng/mL or transferrin saturation <20%, IV-only if ferritin 75-100 ng/mL, explicitly "different than for the general population"; PMID 39324694, 2025-winkelman-aasm-guideline-rls.md), the 2018 IRLSSG iron guideline (oral iron possibly effective at ferritin <=75 ug/L; 2018-allen-irlssg-iron-treatment-guidelines.md), and the 2024 German DGN/DGSM guideline (oral iron for mild RLS at ferritin <=75 ug/L, including in pregnancy; 2024-trenkwalder-german-dgn-dgsm-guideline.md).
• Cabergoline is essentially universally discouraged where guidelines address it, on cardiac valvulopathy grounds: a strong recommendation against in the 2025 AASM guideline (PMID 39324694), a "rarely used" flag in the 2016 AAN guideline (2016-winkelman-aan-treatment-guideline.md), and identified as one of only two items with strong global consensus (alongside valproic acid) in a 53-society World Sleep Society survey (2025-ferri-world-sleep-society-endorsement.md).
• The IRLSSG's essential diagnostic criteria (updated 2014, five criteria including differential-diagnosis exclusion) function as the shared diagnostic backbone underlying every guideline reviewed here, explicitly adopted by the German DGN/DGSM guideline (2024-trenkwalder-german-dgn-dgsm-guideline.md) and referenced as the international consensus standard in a Japanese review of Japan's own 2024 guideline (2025-tsuboi-japanese-rls-guideline-review.md); see 2014-allen-irlssg-updated-diagnostic-criteria.md for the primary criteria.
• Guideline consensus on augmentation management itself is stable and convergent: correct or remove aggravating factors first, do not increase the causative dopaminergic drug, and switch/taper under supervision - present in the 2016 IRLSSG/EURLSSG augmentation guideline (2016-garcia-borreguero-augmentation-prevention-treatment-guidelines.md), the 2026 Mayo/RLS-Foundation algorithm (2026-silber-updated-rls-management-algorithm.md), and the AASM 2025 good-practice statement to address exacerbating factors first (PMID 39324694).

Emerging C

• A 2025 World Sleep Society survey of 53 affiliated national sleep societies (23 respondents, 43.9% response rate, all inhabited continents) found 12 of 20 AASM 2025 recommendations fully supported internationally, 5 partially supported, and meaningful regional disagreement concentrated specifically on the two recommendations against dopamine agonist use (2025-ferri-world-sleep-society-endorsement.md) - suggesting the augmentation-avoidance consensus is real but not yet uniformly accepted worldwide.
• Guideline-recommended augmentation management works when applied: a 63-patient cohort managed by cross-titration to alpha-2-delta ligands and/or opioids per existing guidelines found 78% responders, with responders more likely to have fully discontinued the dopamine agonist (59% vs 40% of non-responders) (2022-yeung-laiwah-augmentation-guideline-effectiveness.md).
• Real-world adherence to guideline recommendations lags behind the recommendations themselves: a 2025 Spanish cohort of 93 patients with confirmed augmentation found 85% remained on a dopamine agonist and only 20% of those had a dose reduction (2025-martin-garcia-spanish-augmentation-cohort.md).
• The 2025 AASM guideline is more permissive toward opioids than most other guidelines reviewed here, giving a conditional recommendation FOR extended-release oxycodone/other opioids "over no opioids" as a general option (moderate certainty of evidence) rather than framing them strictly as a last-resort bridge (PMID 39324694, 2025-winkelman-aasm-guideline-rls.md) - a newer, less-tested positioning compared with the refractory-only framing in the French 2018 consensus (2018-chenini-french-consensus-pharmacoresistant.md) and the German 2024 guideline (2024-trenkwalder-german-dgn-dgsm-guideline.md).
• Device-based therapy is an emerging but unsettled area: the 2025 AASM guideline gives a conditional recommendation for bilateral high-frequency peroneal nerve stimulation (PMID 39324694), a newer device modality not yet addressed by the German 2024 guideline's device discussion (2024-trenkwalder-german-dgn-dgsm-guideline.md).

Contested or negative findings

• Direct cross-guideline disagreement on whether dopamine agonists belong among first-line options at all: the 2025 AASM guideline conditionally recommends AGAINST standard pramipexole/ropinirole/ rotigotine use (PMID 39324694, 2025-winkelman-aasm-guideline-rls.md), while the 2024 German DGN/DGSM guideline still lists non-ergot dopamine agonists alongside gabapentinoids as first-line therapy (2024-trenkwalder-german-dgn-dgsm-guideline.md), and the 2018 French consensus treats dopaminergic agonists as one of three equally-weighted first-line drug classes (2018-chenini-french-consensus-pharmacoresistant.md). Same augmentation evidence base, different national conclusions.
• Direct disagreement on pneumatic compression devices: the 2018 Movement Disorder Society review classifies IV ferric carboxymaltose and pneumatic compression as newly "likely efficacious" (2018-winkelmann-mds-evidence-based-review.md), while the 2024 German DGN/DGSM guideline states pneumatic compression, acupuncture, endovascular laser ablation, cryotherapy, and phytotherapy "cannot be recommended at present due to lack of data" (2024-trenkwalder-german-dgn-dgsm-guideline.md).
• Dipyridamole is a genuinely contested recommendation: the 2025 AASM guideline gives a conditional recommendation FOR it (low certainty of evidence; PMID 39324694), yet the World Sleep Society survey of national societies found dipyridamole was the single AASM recommendation NOT supported internationally (2025-ferri-world-sleep-society-endorsement.md).
• The clearest documented guideline reversal: the 2012 AASM practice parameters gave pramipexole and ropinirole a STANDARD (highest) level recommendation (2012-aurora-aasm-practice-parameters.md), while the same organization's 2025 guideline conditionally recommends against standard use of the same two drugs (PMID 39324694, 2025-winkelman-aasm-guideline-rls.md) - a within-organization reversal driven entirely by accumulated augmentation evidence over 13 years, not new drug-efficacy data.
• The original 2004 RLS Foundation Medical Advisory Board algorithm positioned dopamine agonists and levodopa as central pharmacologic options (2004-silber-mayo-clinic-original-algorithm.md); the same advisory board's 2021 and 2026 updates instead lead with alpha-2-delta ligands and reposition dopamine agonists as second-line (2021-silber-mayo-clinic-rls-algorithm.md, 2026-silber-updated-rls-management-algorithm.md) - a second independent example of guideline reversal within one authorship lineage.

Mechanistic picture in 5 bullet points

• Guidelines converge on treating RLS as a brain (not just peripheral) iron-insufficiency disorder interacting with dopaminergic signalling rather than simple dopamine deficiency, which is the stated rationale for near-universal serum ferritin/transferrin-saturation testing at diagnosis and at any symptom worsening (PMID 39324694, 2025-winkelman-aasm-guideline-rls.md; 2024-trenkwalder-german-dgn-dgsm-guideline.md).
• Chronic dopamine agonist exposure is treated by guidelines as mechanistically causal for augmentation (via presumed receptor-level adaptation), which is why every guideline addressing the topic recommends capping dose at the lowest effective level and using only one dopaminergic agent rather than escalating (2016-garcia-borreguero-augmentation-prevention-treatment-guidelines.md; 2024-trenkwalder-german-dgn-dgsm-guideline.md).
• Alpha-2-delta ligands are guideline-preferred as durable therapy because they act through a distinct (calcium-channel/glutamatergic) mechanism from dopamine agonists, which guidelines cite as the reason they do not carry the same augmentation liability over multi-year use (2013-garcia-borreguero-irlssg-long-term-guidelines.md; PMID 39324694).
• Peripheral (serum) and central (brain/CSF) iron status can be dissociated, which is why the ferritin thresholds guidelines set for RLS (around 75 ng/mL, and even higher via the 75-100 ng/mL IV-iron band in the 2025 AASM guideline) are explicitly higher than thresholds used to diagnose iron-deficiency anemia in the general population (PMID 39324694, 2025-winkelman-aasm-guideline-rls.md).
• Augmentation is treated across guidelines as a drug-induced pharmacodynamic phenomenon that is reversible by removing/reducing the causative drug, rather than as a marker of disease progression - the basis for every reviewed guideline's management step being "remove aggravating factors, then switch/taper" rather than "increase the dose to compensate" (2016-garcia-borreguero-augmentation-prevention-treatment-guidelines.md; 2026-silber-updated-rls-management-algorithm.md).

Implications for a non-drug long-term plan for people currently on dopamine agonists or alpha-2-delta ligands

• Get serum ferritin and transferrin saturation checked and iron corrected first - this is the one recommendation shared, with closely matching numeric thresholds (~75 ug/L or ng/mL), across the US AASM 2025 guideline, the international IRLSSG 2018 iron guideline, and the German 2024 guideline (PMID 39324694, 2025-winkelman-aasm-guideline-rls.md; 2018-allen-irlssg-iron-treatment-guidelines.md; 2024-trenkwalder-german-dgn-dgsm-guideline.md).
• Never increase a dopamine agonist dose to chase worsening symptoms - every guideline that addresses augmentation treats dose escalation as the trigger to reassess, not a valid response (2016-garcia-borreguero-augmentation-prevention-treatment-guidelines.md; 2024-trenkwalder-german-dgn-dgsm-guideline.md); any dose change or taper must be physician-supervised and never abrupt.
• Alpha-2-delta ligands (gabapentin, pregabalin, gabapentin enacarbil) are the one drug class with the broadest cross-guideline support as a durable, lower-augmentation-risk alternative to a dopamine agonist, spanning the US, IRLSSG/EURLSSG, MDS, and (as a co-first-line option) Germany (2025-winkelman-aasm-guideline-rls.md, 2016-garcia-borreguero-augmentation-prevention-treatment-guidelines.md, 2018-winkelmann-mds-evidence-based-review.md, 2024-trenkwalder-german-dgn-dgsm-guideline.md) - a reasonable, physician-discussed substitution target for someone trying to move off a dopamine agonist, though alpha-2-delta ligands are themselves long-term medications, not a drug-free endpoint.
• Do not assume every non-drug device or supplement is guideline-endorsed everywhere: pneumatic compression is "likely efficacious" per the 2018 MDS review but explicitly unsupported "due to lack of data" per the 2024 German guideline (2018-winkelmann-mds-evidence-based-review.md, 2024-trenkwalder-german-dgn-dgsm-guideline.md), and the German guideline separately advises against cannabinoids, magnesium, and benzodiazepines as RLS treatments (2024-trenkwalder-german-dgn-dgsm-guideline.md) - check the specific evidence for any adjunct rather than assuming international consensus.
• Expect a real-world execution gap even when a guideline-concordant plan exists: most patients with confirmed augmentation in routine practice are not switched off dopamine agonists or dose-reduced despite guideline recommendations (2025-martin-garcia-spanish-augmentation-cohort.md), while a cohort that was actively cross-titrated per guideline achieved 78% response (2022-yeung-laiwah-augmentation-guideline-effectiveness.md) - a written, physician-reviewed, actively followed plan appears to matter more than the mere existence of a guideline.
• Low-dose opioids, where used, should be understood as a physician-supervised pharmacologic bridge for refractory cases in most guideline traditions (Germany, France, IRLSSG/Mayo lineage), even though the 2025 AASM guideline frames them somewhat more broadly (2024-trenkwalder-german-dgn-dgsm-guideline.md, 2018-chenini-french-consensus-pharmacoresistant.md, 2026-silber-updated-rls-management-algorithm.md, PMID 39324694) - not a "non-drug" option, and not guideline-endorsed as a first choice anywhere.

Open questions

• Whether the 2025 AASM guideline's GRADE-methodology conclusions against dopamine agonists will be adopted at the next revision cycle by guideline bodies that currently still list DAs as first-line (Germany 2024, France 2018) is unknown; no scheduled joint-harmonization process was identified.
• This sweep could not confirm the existence of a dedicated, PubMed- or web-indexed national RLS guideline for Canada, Australia, China, or India (a Canadian Sleep Society patient brochure and a Chinese stroke-related sleep-disorders consensus mentioning RLS were found, but neither is a dedicated RLS practice guideline); it is unclear whether such guidelines exist only in non-indexed local-language sources, are informal/unpublished, or genuinely do not exist.
• A confirmed, text-extractable primary source for the current Spanish (SEN/SES) and full Japanese (JSNT 2024) guidelines could not be obtained in this sweep (the Spanish PDF was an unreadable image scan; the Japanese guideline was only accessible via a secondary narrative review) - their specific numeric thresholds and recommendation grades remain unconfirmed here (2013-sen-ses-spanish-rls-guideline.md, 2025-tsuboi-japanese-rls-guideline-review.md).
• The evidence disagreement over device-based non-drug therapies (pneumatic compression, peroneal nerve stimulation, infrared light, tsDCS) has not been reconciled between guideline bodies; no head-to-head meta-analysis reconciling the AASM/MDS-permissive stance with the German DGN-skeptical stance was found in this sweep.
• Whether real-world de-prescribing outcomes (2022-yeung-laiwah-augmentation-guideline-effectiveness.md, 2025-martin-garcia-spanish-augmentation-cohort.md) generalize outside specialist referral centers to primary-care settings, where most RLS is actually managed, remains untested.

Notes in this topic

New notes written for this sweep:

• 2024-trenkwalder-german-dgn-dgsm-guideline.md - German DGN/DGSM S2k guideline (2024): dopamine agonists AND gabapentinoids both listed first-line; ferritin <=75 ug/L threshold; several devices rated unsupported by evidence.
• 2025-tsuboi-japanese-rls-guideline-review.md - Japanese-language review summarizing Japan's 2024 Society of Neurological Therapeutics guideline and its augmentation-focused treatment algorithm.
• 2018-chenini-french-consensus-pharmacoresistant.md - French expert consensus on pharmacoresistant RLS; three equally-weighted first-line drug classes (DA, alpha-2-delta, opioids) in France.
• 2016-min-korean-rls-review.md - Korean narrative review documenting the shift from dopamine agonists to alpha-2-delta ligands as first-line, in the absence of a distinct Korean society guideline.
• 2013-sen-ses-spanish-rls-guideline.md - Spanish SEN/SES guideline document (existence and scope confirmed; full text not extractable, so numeric thresholds not reported).
• 2012-aurora-aasm-practice-parameters.md - 2012 AASM practice parameters: pramipexole/ropinirole rated STANDARD (highest), later reversed by the 2025 AASM guideline.
• 2004-silber-mayo-clinic-original-algorithm.md - original 2004 RLS Foundation algorithm; dopamine agonists/levodopa central, later repositioned second-line by the same body's 2021/2026 updates.

Pre-existing guideline notes found in the knowledge base (tagged into this topic; content unchanged):

• 2025-winkelman-aasm-guideline-rls.md (PMID 39324694) - central 2025 AASM guideline: strong FOR gabapentinoids and IV FCM, conditional AGAINST pramipexole/ropinirole/rotigotine, strong AGAINST cabergoline, conditional FOR opioids and peroneal nerve stimulation.
• 2026-silber-updated-rls-management-algorithm.md - 2026 update of the Mayo/RLS-Foundation algorithm; gabapentinoids first-line, expanded low-dose-opioid and peroneal-nerve-stimulation guidance.
• 2021-silber-mayo-clinic-rls-algorithm.md - 2021 Mayo/RLS-Foundation algorithm; first repositioning of dopamine agonists to second-line.
• 2018-allen-irlssg-iron-treatment-guidelines.md - IRLSSG iron guideline: IV FCM first-line for ferritin <300 ug/L; oral iron possibly effective at ferritin <=75 ug/L.
• 2018-winkelmann-mds-evidence-based-review.md - Movement Disorder Society evidence review; IV FCM and pneumatic compression newly "likely efficacious."
• 2016-garcia-borreguero-augmentation-prevention-treatment-guidelines.md - IRLSSG/EURLSSG/RLS-Foundation augmentation prevention/treatment guideline; the core cross-titration algorithm.
• 2016-winkelman-aan-treatment-guideline.md - 2016 AAN guideline; still rated pramipexole/rotigotine Level A, showing the pre-augmentation-era standard of care.
• 2013-garcia-borreguero-irlssg-long-term-guidelines.md - IRLSSG long-term (6+ month) evidence grading by drug and duration.
• 2014-allen-irlssg-updated-diagnostic-criteria.md - the shared IRLSSG diagnostic criteria underlying every guideline reviewed.
• 2014-picchietti-irlssg-pregnancy-lactation-guideline.md - IRLSSG pregnancy/lactation-specific consensus algorithm.
• 2012-garcia-borreguero-efns-ens-esrs-guideline.md - 2012 European (EFNS/ENS/ESRS) guideline; already flagged durability concerns with dopamine agonists versus rotigotine.
• 2006-vignatelli-efns-rls-plmd-guideline.md - original 2006 EFNS guideline; dopaminergic agents rated best evidence, predating iron therapy as a distinct treatment class.
• 2007-garcia-borreguero-max-planck-augmentation-criteria.md - Max Planck Institute consensus augmentation diagnostic criteria, used internationally.
• 2003-allen-nih-consensus-diagnostic-criteria.md - original NIH/IRLSSG diagnostic and augmentation criteria workshop.
• 2025-ferri-world-sleep-society-endorsement.md - 53-society World Sleep Society survey on international applicability of the AASM 2025 guideline; identifies dopamine-agonist recommendations as the main point of regional disagreement.

Other pre-existing notes referenced for supporting evidence (not guideline documents themselves):

• 2014-allen-nejm-pregabalin-pramipexole-augmentation.md - pivotal RCT: 2.1% pregabalin vs 7.7% pramipexole augmentation, the trial evidence behind the alpha-2-delta-first guideline shift.
• 2011-hogl-pramipexole-6-month-augmentation-rct.md - RCT: 9.2% pramipexole vs 6.0% placebo augmentation at 6 months.
• 2024-qadri-iv-fcm-meta-analysis.md - 2024 meta-analysis (7 RCTs, 537 patients) supporting IV FCM efficacy, underlying the near-universal IV-iron recommendations.
• 2022-yeung-laiwah-augmentation-guideline-effectiveness.md - cohort testing real-world effectiveness of guideline-recommended augmentation management (78% responders).
• 2025-martin-garcia-spanish-augmentation-cohort.md - real-world cohort documenting the gap between augmentation guidelines and routine Spanish clinical practice.

Additional linked notes (2026-09 quality pass)

These notes carry this topic tag but are not yet woven into the prose synthesis above; listed here so they are discoverable and counted in catalog.json rather than orphaned.

• 2015-nhg-dutch-sleep-guideline-rls.md (2015) - The NHG guideline 'Sleep problems and sleeping pills': The Dutch College of General Practitioners (NHG) national primary-care guideline on sleep problems and sleeping pills recommends, for patients with RLS who continue to have major distress despite non-drug advice and n...
• 2025-gorbachev-diagnosis-therapy-elderly-review.md (2025) - Current issues of diagnosis and therapy of patients with restless legs syndrome: This 2025 Russian-language review from Sechenov University (Moscow) summarizes current diagnostic and therapeutic challenges in RLS, using the 2014 International RLS Study Group diagnostic criteria as the reference st...